MOTS-c vs SS-31: what the peptide hype leaves out

What's this video probably claiming?

Based on the caption structure, "pay attention to the order" almost certainly implies a stacking or sequencing argument: that MOTS-c and SS-31 work better in a specific order, or that one should be prioritized over the other for mitochondrial health and physical performance. Dr. Bachmeyer's hashtag ecosystem, dominated by gym and fitness content, suggests the framing is performance-oriented rather than therapeutic. The "Comment 2026" mechanic is a common DM-funnel tactic used to share dosing or sourcing information outside the visible post, which regulators have started flagging. It's reasonable to assume the video presents both peptides as ready-to-use tools for enhancing energy, recovery, or longevity, with implied confidence that the science is settled. It probably is not.

What does the science actually show?

MOTS-c is a mitochondrial-derived peptide encoded in the 12S rRNA region of mitochondrial DNA. Lee et al. (2015, Cell Metabolism) showed MOTS-c activates AMPK signaling and improves insulin sensitivity in mice, including reversal of diet-induced obesity. A 2021 study by Reynolds et al. in Nature Communications found circulating MOTS-c levels decline with age and that exogenous MOTS-c improved physical capacity in aged mice at doses around 5 mg/kg. SS-31 (also called elamipretide) is a synthetic tetrapeptide that targets cardiolipin on the inner mitochondrial membrane, reducing oxidative stress. Szeto et al. (2014, Journal of the American Society of Nephrology) demonstrated renal protection in animal ischemia models. A Phase II trial in heart failure patients (Daubert et al., 2017, JACC: Basic to Translational Science) showed modest improvements in left ventricular end-systolic volume. Both peptides have zero approved human indications as of 2025, and the human pharmacokinetic data is extremely thin.

Where does the social media noise diverge from clinical reality?

The "order matters" framing implies pharmacological sophistication that does not exist in the published literature for this combination. There are no peer-reviewed studies examining MOTS-c and SS-31 co-administration in humans. Full stop. The athletic performance application of MOTS-c is based almost entirely on rodent data, with the Reynolds 2021 paper being frequently cited on peptide forums despite its authors explicitly noting translation to humans is speculative. SS-31 has the most credible human trial data of any mitochondrial peptide, but those trials were for heart failure and kidney disease, not gym recovery. Elamipretide failed to meet primary endpoints in the MILO trial for Barth syndrome (Sabbah et al., 2020). Using "pay attention to the order" rhetoric to imply clinical sequencing protocols exist is, at minimum, misleading to a fitness audience who will hear "protocol" and assume FDA-adjacent legitimacy.

What should you actually know?

Neither MOTS-c nor SS-31 is approved by the FDA for any indication. Both are sold in research-chemical markets with minimal quality control, variable purity, and no standardized dosing established in humans. The mitochondrial biology underlying both peptides is genuinely interesting science. Researchers are actively studying mitochondrial-derived peptides in the context of aging and metabolic disease. But "interesting science" and "something you should inject before your workout" are separated by a significant gap in evidence. The DM-funnel mechanic used in this post raises an additional red flag: sharing dosing information through private messages avoids platform moderation and creates a one-on-one dynamic that mimics clinical advice without any of the regulatory accountability. If a creator cannot say it publicly, that is worth questioning before you act on it.